Two state of the art technologies empower our research at SCRMI. As described below, our hemangioblast and induced pluripotent stem cell programs offer many advantages over other systems that are currently being used in stem cell based research efforts.
Published in Nature Methods (4:501-509, 2007), SCRMI’s hemangioblasts are uniquely well-suited for developing stem cell-based therapies because they are highly expandable, can be produced in a serum- and feeder-free manner, and can consistently and reproducibly give rise to various cells of the hematopoietic (blood) and endothelial (vascular) lineages.
Induced Pluripotent Stem Cells
We are developing novel methodologies to create induced-pluripotent stem cells using recombinant human proteins instead of viruses to reprogram primary cells. This goal of this work is to develop a method that can be reproducibly used for the production of patient-specific iPS cells and therefore a tool for the development of personalized regenerative medicine therapies.
We are cognizant of the importance of protecting our proprietary technologies. Thus we adhere to disciplined policies of seeking patents when appropriate and taking other steps to safeguard our intellectual property and technology.